|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Parke-Davis |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002196 |
Purpose
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
| Condition | Intervention | Phase |
|
HIV Infections |
Drug: CI-1012 |
Phase I |
| MedlinePlus related topics: | AIDS |
| Study Type: | Interventional |
| Study Design: | Treatment, Pharmacokinetics Study |
| Official Title: | A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers. |
Eligibility
| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:
Viral, fungal, or bacterial infection requiring therapy other than topical medications.
Concurrent Medication:
Excluded:
Prior Medication:
Excluded:
Contacts and Locations| United States, California | |||||
| ViRx Inc | |||||
| San Francisco, California, United States, 94109 | |||||
| ViRx Inc | |||||
| Palm Springs, California, United States, 92262 | |||||
| United States, Florida | |||||
| Central Florida Research Initiative | |||||
| Maitland, Florida, United States, 32751 | |||||
| United States, Maryland | |||||
| Natl Institutes of Health | |||||
| Bethesda, Maryland, United States, 20892 | |||||
| Parke-Davis |
More Information
| Study ID Numbers: | 278A, 1012-005 |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002196 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|